Cure Alzheimer’s Fund Welcomes New Board Members to Advance Research

Cure Alzheimer’s Fund, a nonprofit organization committed to funding research aimed at preventing, slowing, or reversing Alzheimer’s disease, has announced the appointment of Christine Villas-Boas and Brittany Bowlen to its Board of Directors. This move is seen as a strategic step to enhance the organization's efforts in combating Alzheimer’s disease through innovative research and philanthropy.

Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund, expressed enthusiasm about the new appointments, highlighting the unique perspectives and passion both individuals bring to the board. Their leadership and commitment to the cause are expected to significantly contribute to the organization's mission.

Christine Villas-Boas, currently serving as President and Treasurer of the Michel and Claire Gudefin Family Foundation, has a personal connection to the cause, having lost her mother to Alzheimer’s in 2015. Her background in banking and finance, coupled with her philanthropic efforts, positions her as a valuable asset to the board. Brittany Bowlen, with her extensive experience in strategy and community impact, including her role as Senior Vice President of Strategy for the Denver Broncos, brings a dynamic approach to tackling the challenges posed by Alzheimer’s disease.

Cure Alzheimer’s Fund has been at the forefront of Alzheimer’s research since its inception in 2004, providing over $232 million in grants to more than 300 leading researchers worldwide. The organization's commitment to transparency and efficiency has earned it a Four-Star rating from Charity Navigator for 13 consecutive years and a Platinum Seal of Transparency from Candid. With the addition of Villas-Boas and Bowlen to its Board of Directors, Cure Alzheimer’s Fund is poised to further its impact in the fight against Alzheimer’s disease. For more information, visit http://curealz.org.